Drug discovery is an adventure, drug delivery is an art. The chemists at Lipocine put their experience to the test — by turning drugs with problematic administration into oral agents with improved bioavailability. With validation from their recently approved testosterone replacement drug, Tlando®, and the licensing potential of three other oral assets for NASH and pre-term birth, Lipocine is now focused on developing oral formulations for depression and epilepsy. Tune in as CEO Mahesh Patel, PhD, describes his development plans.